The Effects of Diagnostic Definitions in Claims Data on Healthcare Cost Estimates: Evidence from a Large-Scale Panel Data Analysis of Diabetes Care in Japan

Haruhisa Fukuda, Shunya Ikeda, Takeru Shiroiwa, Takashi Fukuda

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background: Inaccurate estimates of diabetes-related healthcare costs can undermine the efficiency of resource allocation for diabetes care. The quantification of these costs using claims data may be affected by the method for defining diagnoses. Objectives: The aims were to use panel data analysis to estimate diabetes-related healthcare costs and to comparatively evaluate the effects of diagnostic definitions on cost estimates. Research design: Monthly panel data analysis of Japanese claims data. Subjects: The study included a maximum of 141,673 patients with type 2 diabetes who received treatment between 2005 and 2013. Measures: Additional healthcare costs associated with diabetes and diabetes-related complications were estimated for various diagnostic definition methods using fixed-effects panel data regression models. Results: The average follow-up period per patient ranged from 49.4 to 52.3 months. The number of patients identified as having type 2 diabetes varied widely among the diagnostic definition methods, ranging from 14,743 patients to 141,673 patients. The fixed-effects models showed that the additional costs per patient per month associated with diabetes ranged from US$180 [95 % confidence interval (CI) 178–181] to US$223 (95 % CI 221–224). When the diagnostic definition excluded rule-out diagnoses, the diabetes-related complications associated with higher additional healthcare costs were ischemic heart disease with surgery (US$13,595; 95 % CI 13,568–13,622), neuropathy/extremity disease with surgery (US$4594; 95 % CI 3979–5208), and diabetic nephropathy with dialysis (US$3689; 95 % CI 3667–3711). Conclusions: Diabetes-related healthcare costs are sensitive to diagnostic definition methods. Determining appropriate diagnostic definitions can further advance healthcare cost research for diabetes and its applications in healthcare policies.

Original languageEnglish
Pages (from-to)1005-1014
Number of pages10
JournalPharmacoEconomics
Volume34
Issue number10
DOIs
Publication statusPublished - Oct 1 2016

Fingerprint

Health Care Costs
Japan
Confidence Intervals
Diabetes Complications
Costs and Cost Analysis
Type 2 Diabetes Mellitus
Resource Allocation
Health Services Research
Diabetic Nephropathies
Myocardial Ischemia
Dialysis
Research Design
Extremities
Delivery of Health Care

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Health Policy
  • Public Health, Environmental and Occupational Health

Cite this

The Effects of Diagnostic Definitions in Claims Data on Healthcare Cost Estimates : Evidence from a Large-Scale Panel Data Analysis of Diabetes Care in Japan. / Fukuda, Haruhisa; Ikeda, Shunya; Shiroiwa, Takeru; Fukuda, Takashi.

In: PharmacoEconomics, Vol. 34, No. 10, 01.10.2016, p. 1005-1014.

Research output: Contribution to journalArticle

@article{49bf78aa4e9e46768e82353bcb53aea2,
title = "The Effects of Diagnostic Definitions in Claims Data on Healthcare Cost Estimates: Evidence from a Large-Scale Panel Data Analysis of Diabetes Care in Japan",
abstract = "Background: Inaccurate estimates of diabetes-related healthcare costs can undermine the efficiency of resource allocation for diabetes care. The quantification of these costs using claims data may be affected by the method for defining diagnoses. Objectives: The aims were to use panel data analysis to estimate diabetes-related healthcare costs and to comparatively evaluate the effects of diagnostic definitions on cost estimates. Research design: Monthly panel data analysis of Japanese claims data. Subjects: The study included a maximum of 141,673 patients with type 2 diabetes who received treatment between 2005 and 2013. Measures: Additional healthcare costs associated with diabetes and diabetes-related complications were estimated for various diagnostic definition methods using fixed-effects panel data regression models. Results: The average follow-up period per patient ranged from 49.4 to 52.3 months. The number of patients identified as having type 2 diabetes varied widely among the diagnostic definition methods, ranging from 14,743 patients to 141,673 patients. The fixed-effects models showed that the additional costs per patient per month associated with diabetes ranged from US$180 [95 {\%} confidence interval (CI) 178–181] to US$223 (95 {\%} CI 221–224). When the diagnostic definition excluded rule-out diagnoses, the diabetes-related complications associated with higher additional healthcare costs were ischemic heart disease with surgery (US$13,595; 95 {\%} CI 13,568–13,622), neuropathy/extremity disease with surgery (US$4594; 95 {\%} CI 3979–5208), and diabetic nephropathy with dialysis (US$3689; 95 {\%} CI 3667–3711). Conclusions: Diabetes-related healthcare costs are sensitive to diagnostic definition methods. Determining appropriate diagnostic definitions can further advance healthcare cost research for diabetes and its applications in healthcare policies.",
author = "Haruhisa Fukuda and Shunya Ikeda and Takeru Shiroiwa and Takashi Fukuda",
year = "2016",
month = "10",
day = "1",
doi = "10.1007/s40273-016-0402-3",
language = "English",
volume = "34",
pages = "1005--1014",
journal = "PharmacoEconomics",
issn = "1170-7690",
publisher = "Adis International Ltd",
number = "10",

}

TY - JOUR

T1 - The Effects of Diagnostic Definitions in Claims Data on Healthcare Cost Estimates

T2 - Evidence from a Large-Scale Panel Data Analysis of Diabetes Care in Japan

AU - Fukuda, Haruhisa

AU - Ikeda, Shunya

AU - Shiroiwa, Takeru

AU - Fukuda, Takashi

PY - 2016/10/1

Y1 - 2016/10/1

N2 - Background: Inaccurate estimates of diabetes-related healthcare costs can undermine the efficiency of resource allocation for diabetes care. The quantification of these costs using claims data may be affected by the method for defining diagnoses. Objectives: The aims were to use panel data analysis to estimate diabetes-related healthcare costs and to comparatively evaluate the effects of diagnostic definitions on cost estimates. Research design: Monthly panel data analysis of Japanese claims data. Subjects: The study included a maximum of 141,673 patients with type 2 diabetes who received treatment between 2005 and 2013. Measures: Additional healthcare costs associated with diabetes and diabetes-related complications were estimated for various diagnostic definition methods using fixed-effects panel data regression models. Results: The average follow-up period per patient ranged from 49.4 to 52.3 months. The number of patients identified as having type 2 diabetes varied widely among the diagnostic definition methods, ranging from 14,743 patients to 141,673 patients. The fixed-effects models showed that the additional costs per patient per month associated with diabetes ranged from US$180 [95 % confidence interval (CI) 178–181] to US$223 (95 % CI 221–224). When the diagnostic definition excluded rule-out diagnoses, the diabetes-related complications associated with higher additional healthcare costs were ischemic heart disease with surgery (US$13,595; 95 % CI 13,568–13,622), neuropathy/extremity disease with surgery (US$4594; 95 % CI 3979–5208), and diabetic nephropathy with dialysis (US$3689; 95 % CI 3667–3711). Conclusions: Diabetes-related healthcare costs are sensitive to diagnostic definition methods. Determining appropriate diagnostic definitions can further advance healthcare cost research for diabetes and its applications in healthcare policies.

AB - Background: Inaccurate estimates of diabetes-related healthcare costs can undermine the efficiency of resource allocation for diabetes care. The quantification of these costs using claims data may be affected by the method for defining diagnoses. Objectives: The aims were to use panel data analysis to estimate diabetes-related healthcare costs and to comparatively evaluate the effects of diagnostic definitions on cost estimates. Research design: Monthly panel data analysis of Japanese claims data. Subjects: The study included a maximum of 141,673 patients with type 2 diabetes who received treatment between 2005 and 2013. Measures: Additional healthcare costs associated with diabetes and diabetes-related complications were estimated for various diagnostic definition methods using fixed-effects panel data regression models. Results: The average follow-up period per patient ranged from 49.4 to 52.3 months. The number of patients identified as having type 2 diabetes varied widely among the diagnostic definition methods, ranging from 14,743 patients to 141,673 patients. The fixed-effects models showed that the additional costs per patient per month associated with diabetes ranged from US$180 [95 % confidence interval (CI) 178–181] to US$223 (95 % CI 221–224). When the diagnostic definition excluded rule-out diagnoses, the diabetes-related complications associated with higher additional healthcare costs were ischemic heart disease with surgery (US$13,595; 95 % CI 13,568–13,622), neuropathy/extremity disease with surgery (US$4594; 95 % CI 3979–5208), and diabetic nephropathy with dialysis (US$3689; 95 % CI 3667–3711). Conclusions: Diabetes-related healthcare costs are sensitive to diagnostic definition methods. Determining appropriate diagnostic definitions can further advance healthcare cost research for diabetes and its applications in healthcare policies.

UR - http://www.scopus.com/inward/record.url?scp=84961655039&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84961655039&partnerID=8YFLogxK

U2 - 10.1007/s40273-016-0402-3

DO - 10.1007/s40273-016-0402-3

M3 - Article

C2 - 27016372

AN - SCOPUS:84961655039

VL - 34

SP - 1005

EP - 1014

JO - PharmacoEconomics

JF - PharmacoEconomics

SN - 1170-7690

IS - 10

ER -